Clinical significance of dornase alfa (Pulmozyme) in complex therapy of early age children suffering cystic fybrosis
We considered the pathogenic mechanisms, clinical presentation and principles of treatment of cystic fibrosis. Data for retrospective study of clinical efficacy and safety of long-term administration of recombinant human DNase (dornaza alpha; Pulmozim) in infants with cystic fibrosis are presented. The results confirm the Pulmozim safety and efficacy in this group of patients. The frequency of respiratory episodes is decreased by 42.37 due to Pulmozim administration. It is emphasized that early Pulmozim administration helps in the prevention of respiratory episodes, reduction of inflammatory activity in the lungs, improvement of nutritional status, and in the future - improvement of quality and extended life-span in patients with cystic fibrosis.

Keywords: mucolytic therapy, dornaza alpha, cystic fibrosis, kinesitherapy